===
Emittent / Herausgeber: CureVac / Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
2024-06-24 / 22:05 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
CureVac Announces Voting Results of General Meeting

TÜBINGEN, Germany/BOSTON, USA - June 24, 2024 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today
announced the voting results of the Company's annual general meeting.
The shareholders of the Company voted in favor of all proposals. These proposals included the appointment of Thaminda
Ramanayake and the reappointment of Malte Greune as members of the Management Board, both effective June 24th, 2024.
Additionally, Jean Stéphenne and Mathias Hothum were reappointed as members of the supervisory board, Birgit Hofmann
was appointed as a new member of the Supervisory Board effective June 24th, 2024, and KPMG Accountants N.V. was
reappointed as the external auditors for the financial year 2024.
A table containing tabulations of the votes casted is expected to be released in the coming days.

About CureVac
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more
than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical
purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct
the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered
in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on
CureVac's second-generation mRNA technology. This collaboration was later extended to the development of
second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary
technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies,
antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has
more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S. Further
information can be found at www.curevac.com.

CureVac Media Contact
Patrick Perez, Junior Manager Public Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1831
patrick.perez@curevac.com

CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

Forward-Looking Statements CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the
United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions,
expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned
subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or
future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential
efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway,
growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology
such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would,"
"could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking
statements are based on management's current beliefs and assumptions and on information currently available to the
company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not
place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the
worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and
clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and
collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in
current and proposed legislation, regulations and governmental policies, pressures from increasing competition and
consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of
operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability
to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in
litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the
statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company's control and could cause its actual results to differ materially from those it
thought would occur. The forward-looking statements included in this press release are made only as of the date hereof.
The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future events or developments, except as
required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and
Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
Veröffentlichung einer Mitteilung, übermittelt durch EQS Group AG.
Medienarchiv unter https://www.eqs-news.com.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.  
Sprache:      Deutsch 
Unternehmen:  CureVac 

Friedrich-Miescher-Str. 15
72076 Tübingen
Deutschland
EQS News ID: 1931849

Ende der Mitteilung EQS News-Service

===
Bildlink: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1931849&application_name=news

END) Dow Jones Newswires

June 24, 2024 16:05 ET (20:05 GMT)